Blood Vessels, Thrombosis & Hemostasis最新文献

{"title":"Low incidence of thromboembolism with Fiix-monitored warfarin compared to conventional warfarin and DOACs in patients with AF","authors":"Arnar B. Ingason ,&nbsp;Brynja R. Gudmundsdottir ,&nbsp;Ragnar Palsson ,&nbsp;Johann P. Hreinsson ,&nbsp;Sigrun H. Lund ,&nbsp;Loic R. Letertre ,&nbsp;Edward Rumba ,&nbsp;Arnar S. Agustsson ,&nbsp;Einar S. Bjornsson ,&nbsp;Pall T. Onundarson","doi":"10.1016/j.bvth.2025.100056","DOIUrl":"10.1016/j.bvth.2025.100056","url":null,"abstract":"<div><h3>Abstract</h3><div>Mixed population studies suggest that monitoring only coagulation factors II and X (Fiix) instead of conventional prothrombin time improves clinical outcomes in patients on warfarin. We hypothesized that Fiix-monitored warfarin (Fiix-warfarin) provides better real-world clinical outcomes than PT based international normalized ratio (PT-INR) monitored warfarin (PT-warfarin), apixaban, dabigatran, and rivaroxaban in non-valvular atrial fibrillation (AF) patients. We performed a retrospective population cohort study over a 5-year period including all long-term orally anticoagulated adult AF patients in the Greater Reykjavik area. Baseline characteristics differences were adjusted using inverse probability of treatment weighting. Principal outcomes were rates of total thromboembolism (TE), all-cause death, and major bleeding. Outcomes with Fiix-warfarin were used as reference. The study population consisted of 6417 patients anticoagulated long-term for 12 914 person-years (py), ie, Fiix-warfarin (n = 1257/py = 2514), PT-warfarin (n = 1904/py = 3998), apixaban (n = 1171/py = 1639), rivaroxaban (n = 1536/py = 3226) or dabigatran (n = 549/py = 1537). PT-warfarin (1.9% per py; hazard ratio (HR) 1.86 [<em>P</em> =.007]), apixaban (1.9% ppy; HR 1.94 [<em>P</em> = .02]), and dabigatran (2.2% ppy; HR 2.19 [<em>P</em> = .01]) had higher TE rates of than Fiix-warfarin (1.1% ppy). Similarly, rivaroxaban trended towards higher TE rates (1.6% ppy; HR 1.58; [<em>P</em> = .07]). Rivaroxaban had significantly higher all-cause mortality rate than Fiix-warfarin (3.0% vs 2.0% ppy; HR 1.48; [<em>P</em> =.04]). Major bleeding rates were similar. Warfarin anticoagulation variability was lower with Fiix-monitoring than with PT-monitoring. We conclude that Fiix-monitored warfarin could be the most effective long-term oral anticoagulant for patients with AF.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100056"},"PeriodicalIF":0.0,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kinetics of DNases after hematopoietic stem cell transplant","authors":"Azada Ibrahimova ,&nbsp;Nathan Luebbering ,&nbsp;Lucille Langenberg ,&nbsp;Sheyar Abdullah ,&nbsp;Lauren Strecker ,&nbsp;Kelly E. Lake ,&nbsp;Adam Lane ,&nbsp;Aaron Webster ,&nbsp;Kasiani C. Myers ,&nbsp;Sonata Jodele ,&nbsp;Stella M. Davies","doi":"10.1016/j.bvth.2025.100055","DOIUrl":"10.1016/j.bvth.2025.100055","url":null,"abstract":"<div><h3>Abstract</h3><div>The entire hematopoietic system is rapidly lysed over 8 to 10 days during hematopoietic stem cell transplant (HSCT), releasing toxic intracellular molecules such as cell-free DNA (cfDNA) and proteins such as actin into the circulation. Neutrophil extracellular traps released at the time of engraftment also contribute to the cfDNA burden. Clearance of cfDNA is essential for limiting tissue toxicity. We measured levels of cfDNA, DNase I and DNase1L3 in 108 consecutive patients receiving allogeneic HSCT at baseline and on days 0, 7, 14, 30, and 100. cfDNA levels peak at day 14 and are higher in patients with endothelial injury. DNase I levels are depleted on day 7, recovering quickly by day 14, and remain above baseline at day 100. DNase1L3 levels decreased below baseline at day 0, reached a nadir by day 7, but recovered by day 30 remaining above baseline at day 100. Patients with a periengraftment oxygen requirement and those with transplant-associated thrombotic microangiopathy had higher DNase I levels than those without. DNase1L3 levels did not influence any HSCT outcomes. We analyzed DNase I activity using plasmid DNA degradation and showed decreased activity on days 0 and 7, in agreement with reduced protein levels. Further studies are needed to understand the dynamics of DNases in patients undergoing HSCT, to assess their potential role in HSCT toxicities.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100055"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143687950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematologists’ comfort and experiences with providing care to transgender youth","authors":"Eric S. Mullins ,&nbsp;Tanya L. Kowalczyk Mullins","doi":"10.1016/j.bvth.2025.100054","DOIUrl":"10.1016/j.bvth.2025.100054","url":null,"abstract":"<div><h3>Abstract</h3><div>Transgender and gender-diverse (TG) people with preexisting risk factors for thrombosis may seek hematologic evaluation before starting gender-affirming hormone therapy (GAHT). Because no formal guidelines on management of thrombosis risk exist, variations in management are likely to occur. We characterized hematologists’ experience and comfort with caring for TG youth and explored experiences with recommending thromboprophylaxis before GAHT. Hematologists caring for youth aged ≤22 years and practicing in the midwestern United States completed semistructured interviews assessing demographics, practice characteristics, comfort with caring for TG people, education in TG clinical care, suggested interventions to improve comfort, and experiences with recommending and/or prescribing thromboprophylaxis before GAHT. Of the 15 hematologists interviewed (12 pediatric, 2 adult, and 1 dual trained), nearly all had cared for TG adolescents (n = 12) or young adults (n = 14). Participants reported variable comfort with asking about name and pronouns and knowledge about the gender transition process. Although most hematologists reported having had some education about TG clinical care, this primarily occurred after formal training was completed. Suggested interventions to increase comfort with caring for TG youth included educating hematologists about gender care, changes in the electronic medical record, and more data on thrombosis risk associated with GAHT. One-third of participants had recommended and started thromboprophylaxis for patients before GAHT. Five additional hematologists had evaluated youths before GAHT but had not recommended thromboprophylaxis. Because hematologists are evaluating patients for potential thromboprophylaxis before GAHT, education about caring for TG people and data about thrombosis risk are needed to improve care for this population.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100054"},"PeriodicalIF":0.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143601656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of sickle trait on maternal and perinatal outcomes among pregnant women","authors":"Sarah Sewaralthahab ,&nbsp;Jiling Chou ,&nbsp;Stephen Fernandez ,&nbsp;Nawar Shara ,&nbsp;Hedy P. Smith","doi":"10.1016/j.bvth.2025.100049","DOIUrl":"10.1016/j.bvth.2025.100049","url":null,"abstract":"<div><h3>Abstract</h3><div>The risk of multiple adverse pregnancy outcomes and perinatal outcomes among pregnant women with sickle cell trait (SCT) is not known. Our objective was to compare differences in adverse outcomes, specifically pregnancy-related hypertensive disease (PRHD), pyelonephritis/urinary tract infection (UTI), and low birth weight (LBW), between pregnant women with SCT and healthy controls. This was a retrospective cohort study of women who delivered between 2015 and 2020. We included all women with SCT, that is, hemoglobin electrophoresis AS. Women with SCT were matched in a 1:2 to women without SCT, controlling for age, gravidity, and parity. Our primary outcomes were PRHD, pyelonephritis/UTI, and LBW baby. Multivariable logistic regression modeling examined the associations between patients’ characteristics and the primary outcomes.There were 162 women with SCT, and 324 healthy control women were enrolled. Bivariate analysis revealed that women with SCT had a higher proportion of PRHD (38.9% vs 34.9%; <em>P</em> = .39), pyelonephritis/UTI (11.7% vs 7.1%; <em>P</em> = .09), but a lower proportion of LBW (10.5% vs 16.0%; <em>P</em> = .1). In multivariable analysis, after controlling for confounders, SCT was not an independent predictor of PRHD. However, SCT was an independent predictor of pyelonephritis/UTI (adjusted odds ratio [aOR], 1.98; 95% confidence interval [CI], 1.02-3.85) and of a lower risk of having a LBW baby (aOR, 0.48; 95% CI, 0.25-0.94). SCT is not associated with an increased risk of PRHD. However, SCT is associated with pregnancy outcomes, including higher risk of pyelonephritis/UTI but a lower risk of LBW babies.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100049"},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143601310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A NOTCH4 intron 28 regulatory element controls arterial specification and lymphoid development from hPSCs","authors":"Ho Sun Jung ,&nbsp;Divine Mensah Sedzro ,&nbsp;Peng Liu ,&nbsp;Igor I. Slukvin","doi":"10.1016/j.bvth.2025.100046","DOIUrl":"10.1016/j.bvth.2025.100046","url":null,"abstract":"<div><h3>Abstract</h3><div>NOTCH signaling plays a critical role in arterial specification, and the formation of transient definitive lymphomyeloid progenitors and hematopoietic stem cells from hemogenic endothelium (HE). To investigate NOTCH signaling mechanisms critical for arterial and lymphoid specification, we performed single-cell multiomics analysis of human pluripotent stem cells (hPSCs) at different stages of hematopoietic differentiation. These studies uncovered the activation of NOTCH signaling and the arterial program, along with dynamic changes in related regulons throughout the HE specification and the endothelial-to-hematopoietic transition. We revealed that expression of NOTCH4 in the arterial endothelium is controlled by a <em>cis</em>-regulatory element within intron 28 (<em>NOTCH4in28</em>) through SOX17 binding. Deletion of <em>NOTCH4in28</em> in conventional and conditional iSOX17 hPSCs impaired the formation of the early wave DLL4⁺CXCR4^+/− HE with arterial features, as well as hematopoietic progenitors with T and natural killer lymphoid potential. Collectively, we provide compelling evidence that NOTCH4 and the <em>NOTCH4in28 cis</em>-regulatory element play an important role in arterial specification and lymphoid development in hPSC cultures.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100046"},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143839058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seasonal variation in immune thrombotic thrombocytopenic purpura in New England","authors":"Jorge N. Ruiz Lopez ,&nbsp;Ishan Tatake ,&nbsp;Pavan K. Bendapudi","doi":"10.1016/j.bvth.2025.100050","DOIUrl":"10.1016/j.bvth.2025.100050","url":null,"abstract":"","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100050"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regression of pathological blood vessels by inhibition of mast cell function","authors":"WonKyung J. Cho ,&nbsp;Sharad K. Mittal ,&nbsp;Aastha Singh ,&nbsp;Elsayed Elbasiony ,&nbsp;Lei Xi ,&nbsp;Olufemi S. Folorunso ,&nbsp;Vinay K. Pulimamidi ,&nbsp;Sunil K. Chauhan","doi":"10.1016/j.bvth.2025.100044","DOIUrl":"10.1016/j.bvth.2025.100044","url":null,"abstract":"","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100044"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143833229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small-molecule inhibitor screen to identify mechanisms of sickle hemoglobin clearance by liver endothelium","authors":"Tomasz W. Kaminski ,&nbsp;Hong Zhang ,&nbsp;Omika Katoch ,&nbsp;Qizhen Shi ,&nbsp;Gregory J. Kato ,&nbsp;Prithu Sundd ,&nbsp;Tirthadipa Pradhan-Sundd","doi":"10.1016/j.bvth.2025.100045","DOIUrl":"10.1016/j.bvth.2025.100045","url":null,"abstract":"<div><h3>Abstract</h3><div>Intrahepatic accumulation of cell-free hemoglobin (Hb) is a significant pathology linked with hemolytic disorders such as sickle cell disease (SCD). In addition to hepatic Kupffer cells, liver sinusoidal endothelial cells (LSECs) were recently reported to contribute to Hb clearance in SCD mice and patients via currently unknown endocytic mechanism. Using small-molecule inhibitors of endocytic pathway components in primary human and mouse LSECs, we show that sickle-Hb (HbS) uptake by LSECs occurs predominantly through micropinocytosis or fluid-phase endocytosis. However, inhibiting clathrin-mediated endocytosis, receptor recycling, or drop in pH also significantly attenuated HbS uptake by LSECs. LSEC-driven HbS uptake was independent of haptoglobin. Finally, we found that the presence of lipid droplets promotes endothelial HbS internalization, whereas hypolipidemic condition inhibits it. In conclusion, this study identifies previously unknown alternative mechanism of LSEC-mediated HbS internalization. Our findings also inform the need to evaluate the therapeutic potential of blocking these mechanisms to ameliorate hemolysis-associated liver damage in SCD and other hemolytic disorders.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100045"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is it time for nitrated fibrinogen to prove its worth as a risk marker for venous thromboembolism?","authors":"Alessia Arcaro ∗ ,&nbsp;Alessio Lepore ∗ ,&nbsp;Sergio Davinelli ,&nbsp;Giovanni Scapagnini ,&nbsp;Francesco Giallauria ,&nbsp;Paul R. J. Ames ,&nbsp;Fabrizio Gentile","doi":"10.1016/j.bvth.2024.100042","DOIUrl":"10.1016/j.bvth.2024.100042","url":null,"abstract":"","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the structure of β2-glycoprotein I: new insights and future paths for antiphospholipid syndrome","authors":"Suresh Kumar ,&nbsp;Nicola Pozzi","doi":"10.1016/j.bvth.2024.100041","DOIUrl":"10.1016/j.bvth.2024.100041","url":null,"abstract":"<div><h3>Abstract</h3><div>Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent life-threatening blood clots and pregnancy complications in individuals with antiphospholipid antibodies. Among these antibodies, those targeting the plasma glycoprotein β₂-glycoprotein I (β₂GPI) hold particular clinical significance. Despite extensive research, controversies persist regarding the structure of β₂GPI, which has substantial implications for understanding autoantibody reactivity and APS development. This article critically examines recent advancements in the structural biology of β₂GPI and its relevance to the recognition of antiphospholipid antibodies. Additionally, it introduces a new structure-based theory to explain how autoantibodies interact with β₂GPI and the functional consequence of this interaction. Finally, it identifies potential areas for future research that could enhance approaches to diagnosing and treating APS.</div></div>","PeriodicalId":100190,"journal":{"name":"Blood Vessels, Thrombosis & Hemostasis","volume":"2 2","pages":"Article 100041"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143858975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}